LXEO — Lexeo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $713.09m
- $591.34m
- 48
- 12
- 94
- 50
Annual cashflow statement for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.15 | -50.6 | -59.3 | -66.4 | -98.3 |
| Depreciation | |||||
| Non-Cash Items | 1.87 | 0.387 | 2.66 | 4.84 | 13.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.15 | 6.04 | 1.79 | 1.48 | 2.73 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.13 | -44.2 | -54.6 | -59.5 | -81.2 |
| Capital Expenditures | 0 | -0.188 | -0.901 | -0.165 | -0.481 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | — | -93.6 |
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -0.188 | -0.901 | -0.165 | -94.1 |
| Financing Cash Flow Items | -0.224 | -0.372 | 0 | 100 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 32.4 | 151 | 0.189 | 104 | 88.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.2 | 106 | -55.3 | 44.1 | -86.5 |